Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.75 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.75 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.75 |
| ▸ | LTA4H | P09960 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL228100 | 0.98 | PSMB1 (0.78) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| Hydrochloric Acid SCHEMBL228398 | 0.98 | PSMB1 (0.78) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL6442924 | 0.98 | PSMB1 (0.77) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL1027972 | 0.97 | PSMB1 (0.80) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL2741667 | 0.97 | PSMB1 (0.80) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| Hydrochloric Acid SCHEMBL7626127 | 0.94 | PSMB1 (0.72) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL7139772 | 0.94 | PSMB1 (0.71) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL7132076 | 0.94 | PSMB1 (0.71) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL2344523 | 0.93 | PSMB1 (0.74) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| Hydrochloric Acid SCHEMBL7772340 | 0.92 | KDM4E (0.71) | PSMB1PSMB5PSMB2LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157652-A | Preparation method of raloxifene EP impurity B | 深圳菲斯生物科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-120157652-B | Preparation method of raloxifene EP impurity B | SHENZHEN PHYSTANDARD BIOTECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-120157652-A | Preparation method of raloxifene EP impurity B | 深圳菲斯生物科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-118420529-A | Novel estrogen receptor down-regulator compound, preparation method and application | 南京中医药大学 | 2024-08-02 | — | — | CN | disclosed |
| US-20210047297-A1 | 4-(3-AMINO-6-FLUORO-1H-INDAZOL-5-YL)-1,2,6-TRIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DIC ARBONITRILE COMPOUNDS FOR TREATING HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | US | disclosed |
| EP-2526116-B1 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN | ST GEORGES HOSP MEDICAL SCHOOL (GB) | 2015-05-13 | — | — | EP | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8637453-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2014-01-28 | — | — | US | disclosed |
| US-8541363-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | St George's Hosptial Medical School (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2013-08-22 | — | — | US | disclosed |
| EP-0980366-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-02-23 | — | — | EP | disclosed |
| US-6025382-A | Antithrombotic diamines | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0973517-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1998048794-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049160-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998048804-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998048800-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, DPP8 | HRH3 154/4885PSMB1 211/4885PSMB5 484/4885 |
| US-20210047297-A1 | 4-(3-AMINO-6-FLUORO-1H-INDAZOL-5-YL)-1,2,6-TRIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DIC ARBONITRILE COMPOUNDS FOR TREATING HYPERPROLIFERATIVE DISORDERS | PKD1, CDKN1A, VHL | HRH3 144/4885PSMB1 2640/4885PSMB5 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.